The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial

Ian Roberts; Haleema Shakur; Adefemi Afolabi; Karim Brohi; Tim Coats; Yashbir Dewan; Satoshi Gando; Gordon Guyatt; B J Hunt; Carlos Morales; Pablo Perel; David Prieto-Merino; Tom Woolley; CRASH-2 collaborators; Peter Sandercock

doi:10.1016/S0140-6736(11)60278-X

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial

Ian Roberts, Haleema Shakur, Adefemi Afolabi, Karim Brohi, Tim Coats, Yashbir Dewan, Satoshi Gando, Gordon Guyatt, B J Hunt, Carlos Morales, Pablo Perel, David Prieto-Merino, Tom Woolley, CRASH-2 collaborators, Peter Sandercock

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of the CRASH-2 trial was to assess the effects of early administration of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage. Tranexamic acid significantly reduced all-cause mortality. Because tranexamic acid is thought to exert its effect through inhibition of fibrinolysis, we undertook exploratory analyses of its effect on death due to bleeding.

Original language	English
Pages (from-to)	1096-101, 1101.e1-2
Journal	The Lancet
Volume	377
Issue number	9771
DOIs	https://doi.org/10.1016/S0140-6736(11)60278-X
Publication status	Published - 2011

Access to Document

10.1016/S0140-6736(11)60278-X

Cite this

Roberts, I., Shakur, H., Afolabi, A., Brohi, K., Coats, T., Dewan, Y., Gando, S., Guyatt, G., Hunt, B. J., Morales, C., Perel, P., Prieto-Merino, D., Woolley, T., CRASH-2 collaborators, & Sandercock, P. (2011). The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. The Lancet, 377(9771), 1096-101, 1101.e1-2. https://doi.org/10.1016/S0140-6736(11)60278-X

@article{fc41fb6e8c3c4d0cb1154d7f7dd5986f,

title = "The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial",

abstract = "The aim of the CRASH-2 trial was to assess the effects of early administration of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage. Tranexamic acid significantly reduced all-cause mortality. Because tranexamic acid is thought to exert its effect through inhibition of fibrinolysis, we undertook exploratory analyses of its effect on death due to bleeding.",

author = "Ian Roberts and Haleema Shakur and Adefemi Afolabi and Karim Brohi and Tim Coats and Yashbir Dewan and Satoshi Gando and Gordon Guyatt and Hunt, \{B J\} and Carlos Morales and Pablo Perel and David Prieto-Merino and Tom Woolley and \{CRASH-2 collaborators\} and Peter Sandercock",

year = "2011",

doi = "10.1016/S0140-6736(11)60278-X",

language = "English",

volume = "377",

pages = "1096--101, 1101.e1--2",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9771",

}

Roberts, I, Shakur, H, Afolabi, A, Brohi, K, Coats, T, Dewan, Y, Gando, S, Guyatt, G, Hunt, BJ, Morales, C, Perel, P, Prieto-Merino, D, Woolley, T, CRASH-2 collaborators & Sandercock, P 2011, 'The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial', The Lancet, vol. 377, no. 9771, pp. 1096-101, 1101.e1-2. https://doi.org/10.1016/S0140-6736(11)60278-X

TY - JOUR

T1 - The importance of early treatment with tranexamic acid in bleeding trauma patients

T2 - an exploratory analysis of the CRASH-2 randomised controlled trial

AU - Roberts, Ian

AU - Shakur, Haleema

AU - Afolabi, Adefemi

AU - Brohi, Karim

AU - Coats, Tim

AU - Dewan, Yashbir

AU - Gando, Satoshi

AU - Guyatt, Gordon

AU - Hunt, B J

AU - Morales, Carlos

AU - Perel, Pablo

AU - Prieto-Merino, David

AU - Woolley, Tom

AU - CRASH-2 collaborators

AU - Sandercock, Peter

PY - 2011

Y1 - 2011

N2 - The aim of the CRASH-2 trial was to assess the effects of early administration of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage. Tranexamic acid significantly reduced all-cause mortality. Because tranexamic acid is thought to exert its effect through inhibition of fibrinolysis, we undertook exploratory analyses of its effect on death due to bleeding.

AB - The aim of the CRASH-2 trial was to assess the effects of early administration of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage. Tranexamic acid significantly reduced all-cause mortality. Because tranexamic acid is thought to exert its effect through inhibition of fibrinolysis, we undertook exploratory analyses of its effect on death due to bleeding.

U2 - 10.1016/S0140-6736(11)60278-X

DO - 10.1016/S0140-6736(11)60278-X

M3 - Article

C2 - 21439633

SN - 1474-547X

VL - 377

SP - 1096-101, 1101.e1-2

JO - The Lancet

JF - The Lancet

IS - 9771

ER -

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial

Abstract

Access to Document

Fingerprint

Cite this